Salute e Benessere
Multi-Plex Immunoassays Market to Reach US$ 6.90 Billion by 2033 as Precision Medicine and Biomarker Discovery Fuel Global Adoption | DataM Intelligence
With rising demand in the adoption of multi-plex platforms is accelerating across hospitals, diagnostic labs, and biopharma research institutes. Global leaders such as are strengthening portfolios with advanced consumables, reagents, and integrated digital platforms.
Their recurring use in diagnostic workflows ensures stable demand. Technological upgrades in antibody specificity and bead-based assays are fueling double-digit growth in this segment.
remain critical for adoption across clinical and R&D labs. The shift toward fully automated systems is driving higher capital equipment investments.
as demand for data integration, AI-based interpretation, and cloud-enabled diagnostics continues to grow.
making them the dominant segment. Their application in biomarker validation, cancer immunology, and infectious disease testing drives adoption.
are growing rapidly with increased use in molecular diagnostics, infectious disease panels, and oncology liquid biopsies.
supported by demand in biomarker validation and immuno-oncology pipelines.
reflecting adoption in oncology and infectious disease panels.
continue to drive early-stage innovations and academic collaborations.
The U.S., valued at leads global adoption due to:
Japan's market, valued at is expanding rapidly because of:
Thermo Fisher leads with a robust portfolio of protein-based multiplex assays. In 2025, it reported fueled by oncology and autoimmune panels.
Bio-Rad remains a pioneer in bead-based assays. Its 2025 partnerships with Asian clinical labs reinforce its leadership in diagnostics.
Merck is expanding in nucleic acid multiplex assays and biomarker discovery tools, with strategic acquisitions in Europe and Asia .
QIAGEN focuses on multiplex nucleic acid diagnostics, with strong positioning in infectious diseases and liquid biopsy.
Both companies are expanding multiplex solutions for immuno-oncology, with BD leading in hospital adoption and Bio-Techne in translational research.
The is evolving as a core enabler of next-generation diagnostics and drug discovery. Four strategic shifts define its trajectory:
The represents a transformative frontier in diagnostics and therapeutics. With at the forefront, the sector is set to redefine clinical care, drug development, and precision medicine.
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad , Telangana 500039
+1 877-441-4866
Sai.k@datamintelligence.com
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/multi-plex-immunoassays-market-to-reach-us-6-90-billion-by-2033-as-precision-medicine-and-biomarker-discovery-fuel-global-adoption--datam-intelligence-302577061.html